AstraZeneca expands its portfolio through Alexion Pharmaceuticals buyout
AstraZeneca expands its portfolio through Alexion Pharmaceuticals buyout
By Nikita Chaurasia  Date: 2020-12-14

AstraZeneca expands its portfolio through Alexion Pharmaceuticals buyout

British-Swedish multinational pharmaceutical company, AstraZeneca Plc, has reportedly finalized a deal worth USD 39 billion with Alexion Pharmaceuticals Inc., an American pharmaceutical company which specializes in rare disease.

Sources close to the matter stated that the planned cash-and-stock acquisition will help in boosting the development of treatments for immunological and uncommon blood disorders in AstraZeneca’s portfolio, which has always focused on cancer treatments instead. The transaction would also allow AstraZeneca to generate over USD 500 million in the upcoming three years, the company claimed.

The recent development allowed Alexion’s share to be valued at USD 175, a 45% premium to the final price on closing. Sources confirmed that the deal will also establish AstraZeneca a spot among the top 10 drug makers of the world.

Prior to the pandemic, AstraZeneca had showcased 70% growth in value in the last three years as it rolled out cancer drugs such as Tagrisso, Imfinzi, and Lynparza. However, it has been relatively cash-poor since the recent past, and thus will gain benefits from Alexion’s growing business.

During the agreement, every Alexion shareholder will obtain 2.1234 AstaZeneca American depository share and cash worth USD 60. The acquisition will be funded by the British drug maker with USD around 17.5 billion funding provided by Goldman Sachs Group Inc., JPMorgan Chase & Co., and Morgan Stanley.

Geoffrey Porges, an analyst at SVB Leerink, reportedly stated that despite the premium, the price is relatively attractive for AstraZeneca and could further draw out additional offers. Moreover, shareholders of Alexion could hold out for USD 200 per share or seek for a higher cash portion.

A fee of around USD 1.2 billion is included in the contract if Alexion decides to sell itself to another bidder, while AstraZeneca will potentially face a USD 1.4 billion penalty. The deal is scheduled to close in the third quarter of 2021, and Alexion shareholders will own over 15% of the combined companies, sources confirmed.

Source- https://theprint.in/world/astrazeneca-plans-post-covid-growth-with-39-billion-deal-with-alexion-pharmaceuticals/565886/

 

About

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

BMW planning to boost EV production, to sell 250,000 vehicles by 2023
BMW planning to boost EV production, to sell 250,000 vehicles by 2023
By Nikita Chaurasia

The German automaker is planning on introducing around 25 new electric vehicles and plug-in hybrid BMW also intends to develop 1,300 public and 15,000 private charging ports According to reliable sources, German multinational automobile company,...

AstraZeneca’s COVID-19 vaccine may receive EUA from India soon
AstraZeneca’s COVID-19 vaccine may receive EUA from India soon
By Nikita Chaurasia

Reportedly, India intends to grant emergency use ization (EUA) to Oxford/AstraZeneca’s coronavirus vaccine by next week, following submission of some additional data to the concerned ities by a few local manufacturers. India could b...

Tencent Music, Nordic Embassy unite to produce cross-border music album
Tencent Music, Nordic Embassy unite to produce cross-border music album
By Nikita Chaurasia

Tencent Music Entertainment Group (TME), a renowned Chinese music streaming services provider, has reportedly teamed up with the Royal Norwegian Embassy in Beijing to introduce an innovative, classic, and cross-border music album to the Chinese audie...

Amazon urges U.S. officials to prioritize its staff for COVID-19 doses
Amazon urges U.S. officials to prioritize its staff for COVID-19 doses
By Nikita Chaurasia

Amazon.com Inc., an American multinational technology firm, has reportedly asked the government of United States to consider its employees in data center, grocery store, and warehouse to reclassify them as essential workers in order to acquire early ...

Exxon Mobil pledges to drastically reduce GHG emissions by 2025
Exxon Mobil pledges to drastically reduce GHG emissions by 2025
By Nikita Chaurasia

U.S.-based multinational oil and gas company, Exxon Mobil Corporation, under rising pressure from climate change activists and investors, has recently announced a new five-year plan to significantly reduce its carbon footprint. The announcement come...